Difference between revisions of "ICRP Glossary"

From ICRPaedia
Jump to navigation Jump to search
 
(45 intermediate revisions by the same user not shown)
Line 8: Line 8:
 
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.
 
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.
  
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
+
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in [[ICRP publications]].
  
 
----
 
----
 
{| class="wikitable"
 
{| class="wikitable"
 
|-
 
|-
| [[#A|A]] || [[#B|B]]  || [[#C|C]]|| [[#D|D]] || [[#E|E]] || [[#F|F]] || [[#G|G]] || [[#H|H]] || [[#I|I]] || [[#J|J]] || [[#K|K]] || [[#L|L]] || [[#M|M]] ||[[#N|N]] || [[#O|O]] || [[#P|P]] || [[#Q|Q]] || [[#R|R]] || [[#S|S]] || [[#T|T]] || [[#U|U]] || [[#V|V]] || [[#W|W]] || [[#X|X]] || [[#Y|Y]] || [[#Z|Z]] || [[#ZZ|...]]
+
| [[#09|0-9]] || [[#A|A]] || [[#B|B]]  || [[#C|C]]|| [[#D|D]] || [[#E|E]] || [[#F|F]] || [[#G|G]] || [[#H|H]] || [[#I|I]] || [[#J|J]] || [[#K|K]] || [[#L|L]] || [[#M|M]] ||[[#N|N]] || [[#O|O]] || [[#P|P]] || [[#Q|Q]] || [[#R|R]] || [[#S|S]] || [[#T|T]] || [[#U|U]] || [[#V|V]] || [[#W|W]] || [[#X|X]] || [[#Y|Y]] || [[#Z|Z]] || [[#ZZ|...]]
 
|}
 
|}
  
 
<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2">
 
<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2">
 +
 +
=== <big><span id="09">0-9</span></big> ===
 +
 +
*4DCT (see [[Time-resolved computed tomography]])
  
 
=== <big><span id="A">A</span></big> ===
 
=== <big><span id="A">A</span></big> ===
Line 35: Line 39:
  
 
*[[Accountability]]
 
*[[Accountability]]
 +
 +
*[[Accreditation]]
  
 
*[[Action Level]]
 
*[[Action Level]]
  
 
*[[Activation]]
 
*[[Activation]]
 +
 +
*[[Active detection system]]
  
 
*[[Active (red) bone marrow]]
 
*[[Active (red) bone marrow]]
Line 51: Line 59:
  
 
*[[Acute radiation syndrome]]
 
*[[Acute radiation syndrome]]
 +
 +
*[[Additional dose]]
  
 
*[[Adaptive response]]
 
*[[Adaptive response]]
Line 73: Line 83:
  
 
*[[Air-kerma, product]]
 
*[[Air-kerma, product]]
 +
 +
*[[ALARA]]
  
 
*ALI (see [[Annual limit on intake]])
 
*ALI (see [[Annual limit on intake]])
Line 79: Line 91:
  
 
*[[Alimentary tract transfer factor]]
 
*[[Alimentary tract transfer factor]]
 +
 +
*[[Allometry]]
  
 
*[[Alpha decay]]
 
*[[Alpha decay]]
Line 117: Line 131:
  
 
*[[Autoimmune disease]]
 
*[[Autoimmune disease]]
 +
 +
*[[Automatic exposure control]]
  
 
*[[Autonomy]]
 
*[[Autonomy]]
Line 125: Line 141:
  
 
*[[Background dose (rate)]]
 
*[[Background dose (rate)]]
 +
 +
*[[Backscatter detection system]]
  
 
*[[Backscatter factor]]
 
*[[Backscatter factor]]
Line 207: Line 225:
  
 
*[[Class SR-2 gases]]
 
*[[Class SR-2 gases]]
 +
 +
*[[Clearance]]
  
 
*[[Clearance level]]
 
*[[Clearance level]]
Line 221: Line 241:
  
 
*[[Cobblestone area forming cell assay]]
 
*[[Cobblestone area forming cell assay]]
 +
 +
*[[Collective dose]]
  
 
*[[Co-expertise]]
 
*[[Co-expertise]]
Line 228: Line 250:
 
*[[Collective dose]]
 
*[[Collective dose]]
  
*[[Collective effective dose]], S
+
*[[Collective effective dose]]
  
 
*[[Collimation]]
 
*[[Collimation]]
  
 
*[[Colony]]
 
*[[Colony]]
 +
 +
*[[Commissioning]]
  
 
*[[Committed effective dose]]
 
*[[Committed effective dose]]
Line 239: Line 263:
  
 
*[[Compartment]]
 
*[[Compartment]]
 +
 +
*[[Compartment (environmental)]]
  
 
*[[Complex tissues]]
 
*[[Complex tissues]]
  
 
*[[Computed tomography dose index]]
 
*[[Computed tomography dose index]]
 +
 +
*[[Concentration ratio]]
  
 
*[[Cone beam computed tomography]]
 
*[[Cone beam computed tomography]]
Line 251: Line 279:
  
 
*[[Constancy test]]
 
*[[Constancy test]]
 +
 +
*[[Containment]]
  
 
*[[Contamination]]
 
*[[Contamination]]
  
 
*[[Coronary heart disease]]
 
*[[Coronary heart disease]]
 +
 +
*[[Cosmic radiation]]
  
 
*[[Cost-benefit analysis]]
 
*[[Cost-benefit analysis]]
  
 
*[[Coster-Kronig transition]]
 
*[[Coster-Kronig transition]]
 +
 +
*CR (see [[Concentration ratio]])
  
 
*[[Cross section]]
 
*[[Cross section]]
  
*[[Cumulative air kerma]]
+
*Cumulative air kerma (see [[Air kerma at the patient entrance reference point]])
  
 
*[[Cumulative dose]]
 
*[[Cumulative dose]]
Line 273: Line 307:
  
 
*DAC (see [[Derived air concentration]])
 
*DAC (see [[Derived air concentration]])
 +
 +
*DBT (see [[Digital breast tomosynthesis]])
 +
 +
*DCRL (see [[Derived consideration reference level]])
  
 
*DD (see [[Doubling dose]])
 
*DD (see [[Doubling dose]])
 +
 +
*DDI, detector dose indicator (see [[Exposure index]])
  
 
*DIL (see [[Derived investigation level]])
 
*DIL (see [[Derived investigation level]])
Line 287: Line 327:
  
 
*[[Decontamination factor]]
 
*[[Decontamination factor]]
 +
 +
*[[Dental and maxillofacial imaging]]
  
 
*[[Deontological Ethics]]
 
*[[Deontological Ethics]]
  
*[[Deposition]]
+
*[[Deposition]] (inhalation)
  
 
*[[Derived air concentration]]
 
*[[Derived air concentration]]
 +
 +
*[[Derived consideration reference level]]
  
 
*[[Derived investigation level]]  
 
*[[Derived investigation level]]  
 +
 +
*[[Derived limit]]
 +
 +
*[[Derived reference level]]
 +
 +
*[[Designated area]]
 +
 +
*Detector dose indicator (see [[Exposure index]])
 +
 +
*[[Detector quantum efficiency]]
  
 
*[[Deterministic effect]]
 
*[[Deterministic effect]]
Line 301: Line 355:
  
 
*[[Detriment-adjusted risk]]
 
*[[Detriment-adjusted risk]]
 +
 +
*[[Diagnostic reference level]]
  
 
*[[Diastasis]]
 
*[[Diastasis]]
Line 309: Line 365:
  
 
*[[Differentiation]]
 
*[[Differentiation]]
 +
 +
*[[Digital breast tomosynthesis]]
  
 
*[[Dignity]]
 
*[[Dignity]]
Line 321: Line 379:
  
 
*[[Distribution coefficient]] (''K<sub>d</sub>'')
 
*[[Distribution coefficient]] (''K<sub>d</sub>'')
 +
 +
*DLP (see [[Dose-length product]])
  
 
*[[DNA damage signalling]]
 
*[[DNA damage signalling]]
Line 342: Line 402:
 
*[[Dose criteria]]
 
*[[Dose criteria]]
  
*[[Dose of record (E)]]
+
*[[Dose equivalent]] in an organ or tissue
  
*[[Dose of record Hp (10)]]
+
*[[Dose limit]]
  
*[[Dose equivalent in an organ or tissue]]
+
*[[Dose modifying factor]]
  
*[[Dose limit]]
+
*[[Dose of record (E)]]
  
*[[Dose modifying factor]]
+
*[[Dose of record Hp (10)]]
  
 
*[[Dose per content function]]
 
*[[Dose per content function]]
Line 359: Line 419:
  
 
*[[Dose rate effectiveness factor]]
 
*[[Dose rate effectiveness factor]]
 +
 +
*[[Dose-length product]]
  
 
*[[Dose-threshold hypothesis]]
 
*[[Dose-threshold hypothesis]]
Line 369: Line 431:
  
 
*[[Doubling dose]]
 
*[[Doubling dose]]
 +
 +
*DQE (see [[Detector quantum efficiency]])
 +
 +
*DRL (see [[Diagnostic reference level]])
 +
 +
*[[DRL process]]
 +
 +
*[[DRL quantity]]
 +
 +
*[[DRL value]]
  
 
*[[DS02]]
 
*[[DS02]]
Line 393: Line 465:
  
 
*[[Effective half-life]]
 
*[[Effective half-life]]
 +
 +
*EI (see [[Exposure index]])
  
 
*[[Electron-capture decay]]
 
*[[Electron-capture decay]]
Line 411: Line 485:
  
 
*[[Emergency procedures]]
 
*[[Emergency procedures]]
 +
 +
*[[Employer]]
  
 
*[[Endogeneous excretion]]
 
*[[Endogeneous excretion]]
Line 441: Line 517:
  
 
*[[Ethics]]
 
*[[Ethics]]
 +
 +
*[[Evacuation]]
  
 
*[[Excess absolute risk]]
 
*[[Excess absolute risk]]
Line 449: Line 527:
  
 
*[[Excretion rate (instantaneous)]]
 
*[[Excretion rate (instantaneous)]]
 +
 +
*[[Exclusion]]
  
 
*[[Exempt waste]]
 
*[[Exempt waste]]
Line 455: Line 535:
  
 
*[[Existing exposure situation]]
 
*[[Existing exposure situation]]
 +
 +
*[[Exogenous excretion]]
  
 
*[[Expanded and aligned radiation field]]
 
*[[Expanded and aligned radiation field]]
Line 461: Line 543:
  
 
*[[Exponential survival curve]]
 
*[[Exponential survival curve]]
 +
 +
*[[Exposed individuals]]
  
 
*[[Exposure, external or internal]]
 
*[[Exposure, external or internal]]
  
 
*[[Exposure (in the context of inhalation)]]
 
*[[Exposure (in the context of inhalation)]]
 +
 +
*[[Exposure index]]
  
 
*[[Exposure pathway]]
 
*[[Exposure pathway]]
Line 483: Line 569:
  
 
*[[Fluoroscopically guided interventions]]
 
*[[Fluoroscopically guided interventions]]
 +
 +
*[[Fluoroscopically or computed tomography guided interventions]]
  
 
*[[Forbiddenness]]
 
*[[Forbiddenness]]
Line 489: Line 577:
  
 
*[[Fractionation]]
 
*[[Fractionation]]
 +
 +
*[[Fractionation and dose delivery patterns]]
  
 
*[[Fractionation sensitivity]]
 
*[[Fractionation sensitivity]]
 +
 +
*[[Frequent flyer]]
 +
 +
*FSU (see [[Functional subunits]])
 +
 +
*[[Functional subunits]]
  
 
=== <big><span id="G">G</span></big> ===
 
=== <big><span id="G">G</span></big> ===
Line 499: Line 595:
  
 
*[[Gastrointestinal syndrome]]
 
*[[Gastrointestinal syndrome]]
 +
 +
*[[Gastrulation]]
 +
 +
*[[Gastroschisis]]
 +
 +
*[[GATA binding protein 2]]
 +
 +
*GATA-2 (see [[GATA binding protein 2]])
  
 
*[[Genomic integrity]]
 
*[[Genomic integrity]]
 +
 +
*Geomagnetic cut-off rigidity (see [[Rigidity threshold]])
  
 
*[[Graded approach]]
 
*[[Graded approach]]
 +
 +
*[[Graft vs host disease]]
  
 
*[[Granulocyte colony-stimulating factor]]
 
*[[Granulocyte colony-stimulating factor]]
Line 509: Line 617:
  
 
*[[Gray]] (Gy)
 
*[[Gray]] (Gy)
 +
 +
*[[Ground-level enhancement]]
 +
 +
*[[Growth factor]]
  
 
*[[Growth fraction]]
 
*[[Growth fraction]]
Line 522: Line 634:
 
*[[Half-life, physical]]
 
*[[Half-life, physical]]
  
*HATM (see [[Human Alimentary Tract Model]]]
+
*HATM (see [[Human Alimentary Tract Model]])
  
 
*[[Hazard]]
 
*[[Hazard]]
Line 541: Line 653:
  
 
*[[Hormones]]
 
*[[Hormones]]
 +
 +
*[[Hounsfield unit]]
 +
 +
*HRTM (see [[Human Respiratory Tract Model]])
  
 
*[[Human Alimentary Tract Model]]
 
*[[Human Alimentary Tract Model]]
  
*[[Human respiratory tract model]]
+
*[[Human Respiratory Tract Model]]
  
 
*[[Hyperbaric oxygen]]
 
*[[Hyperbaric oxygen]]
 +
 +
*[[Hyperfractionation]]
  
 
*[[Hypertrophic cardiomyopathy]]
 
*[[Hypertrophic cardiomyopathy]]
Line 553: Line 671:
  
 
=== <big><span id="I">I</span></big> ===
 
=== <big><span id="I">I</span></big> ===
 +
 +
*[[ICRU 4-element tissue]]
 +
 +
*[[ICRU sphere]]
  
 
*[[Immune system]]
 
*[[Immune system]]
 +
 +
*IMRT (see [[Intensity-modulated radiotherapy]])
  
 
*[[In vivo radiobioassay]]
 
*[[In vivo radiobioassay]]
Line 581: Line 705:
  
 
*[[Institutional control]]
 
*[[Institutional control]]
 +
 +
*[[Intervention]]
 +
 +
*[[Intensity-modulated radiotherapy]]
  
 
*[[Intake]]
 
*[[Intake]]
Line 619: Line 747:
  
 
=== <big><span id="L">L</span></big> ===
 
=== <big><span id="L">L</span></big> ===
 +
 +
*[[Lag]]
  
 
*[[Late normal tissue responses]]
 
*[[Late normal tissue responses]]
Line 626: Line 756:
 
*[[LD 50/30|LD<sub>50/30</sub>]]
 
*[[LD 50/30|LD<sub>50/30</sub>]]
  
*LET (see *[[Linear energy transfer]])
+
*LET (see [[Linear energy transfer]])
 +
 
 +
*[[Licensee]]
  
 
*[[Life Span Study]]
 
*[[Life Span Study]]
Line 647: Line 779:
  
 
*LLE (see [[Lifetime risk estimates]])
 
*LLE (see [[Lifetime risk estimates]])
 +
 +
*[[Local DRL]]
  
 
*Loss of Life Expectancy (see [[Lifetime risk estimates]])
 
*Loss of Life Expectancy (see [[Lifetime risk estimates]])
Line 673: Line 807:
  
 
*[[Mass median diameter]]
 
*[[Mass median diameter]]
 +
 +
*MDCT (see [[Multi-detector computed tomography]])
 +
 +
*[[Mean glandular dose]]
  
 
*[[Measured quantity]]
 
*[[Measured quantity]]
Line 684: Line 822:
 
*[[Mitigation]]
 
*[[Mitigation]]
  
*MMD (see *[[Mass median diameter]])
+
*MMD (see [[Mass median diameter]])
 +
 
 +
*[[Molecular imaging]]
 +
 
 +
*[[Multifactorial diseases]]
  
 
*[[Multiplicative risk projection model]]
 
*[[Multiplicative risk projection model]]
Line 691: Line 833:
  
 
*[[Multistage tumorigenesis]]
 
*[[Multistage tumorigenesis]]
 +
 +
*[[Multitarget equation]]
 +
 +
*[[Multi-detector computed tomography]]
  
 
*[[Mutation component]]
 
*[[Mutation component]]
Line 699: Line 845:
  
 
=== <big><span id="N">N</span></big> ===
 
=== <big><span id="N">N</span></big> ===
 +
 +
*[[National radon survey]]
 +
 +
*[[National DRL]]
  
 
*[[Naturally occurring radioactive material]]
 
*[[Naturally occurring radioactive material]]
Line 709: Line 859:
  
 
*NHEJ (see [[Non-homologous end joining]])
 
*NHEJ (see [[Non-homologous end joining]])
 +
 +
*[[Noise]] (in imaging)
 +
 +
*[[Nominal value]]
  
 
*[[Nominal risk coefficient]]
 
*[[Nominal risk coefficient]]
Line 721: Line 875:
  
 
*[[Normal tissue complication probability]]
 
*[[Normal tissue complication probability]]
 +
 +
*[[Notification value]] (in CT)
 +
 +
*[[Nuclear medicine]]
  
 
*[[Nuclear track detectors]]
 
*[[Nuclear track detectors]]
  
 
=== <big><span id="O">O</span></big> ===
 
=== <big><span id="O">O</span></big> ===
 +
 +
*OAR (see [[Organ at risk]])
  
 
*[[Occupancy factor]]
 
*[[Occupancy factor]]
  
 
*[[Occupational exposure]]
 
*[[Occupational exposure]]
 +
 +
*OEA (see [[Oxygen enhancement ratio]])
  
 
*[[OLINDA/EXM]]
 
*[[OLINDA/EXM]]
  
 
*[[Oncogene]]
 
*[[Oncogene]]
 +
 +
*[[Operating management]]
 +
 +
*[[Operational quantity]]
  
 
*[[Optimisation]]
 
*[[Optimisation]]
  
*[[Organ/tissue absorbed dose]]
+
*[[Optimisation of protection]]
 +
 
 +
*Organ absorbed dose (see [[Organ/tissue absorbed dose]])
  
*[[Organ absorbed dose]] (see [[Organ/tissue absorbed dose]])
+
*[[Organ at risk]]
  
 
*[[Organ dose equivalent]]
 
*[[Organ dose equivalent]]
 +
 +
*[[Organ/tissue absorbed dose]]
  
 
*[[Other (systemic) tissues]]
 
*[[Other (systemic) tissues]]
Line 747: Line 917:
  
 
*[[Oversight]]
 
*[[Oversight]]
 +
 +
*[[Oxygen enhancement ratio]]
  
 
=== <big><span id="P">P</span></big> ===
 
=== <big><span id="P">P</span></big> ===
Line 752: Line 924:
 
*Particle fluence (see [[Fluence]])
 
*Particle fluence (see [[Fluence]])
  
*[[Particle transport]]
+
*[[Particle transport]] (in biokinetics)
  
 
*[[Particle radiance]]
 
*[[Particle radiance]]
Line 761: Line 933:
  
 
*[[Pelagic]]
 
*[[Pelagic]]
 +
 +
*[[Pencil beam]]
  
 
*[[Percutaneous coronary intervention]]
 
*[[Percutaneous coronary intervention]]
Line 771: Line 945:
  
 
*[[Pharynx]]
 
*[[Pharynx]]
 +
 +
*[[Pilomatricoma]]
  
 
*[[Planned exposure situation]]
 
*[[Planned exposure situation]]
Line 785: Line 961:
  
 
*[[Potential exposure]]
 
*[[Potential exposure]]
 +
 +
*[[Potential recoverability correction factor]]
  
 
*[[Potentially lethal damage repair]]
 
*[[Potentially lethal damage repair]]
  
 
*[[Practical radiological protection culture]]
 
*[[Practical radiological protection culture]]
 +
 +
*[[Practice]]
 +
 +
*PRCF (see [[Potential recoverability correction factor]])
  
 
*[[Prevailing circumstances]]
 
*[[Prevailing circumstances]]
Line 797: Line 979:
  
 
*[[Principle of optimisation]]
 
*[[Principle of optimisation]]
 +
 +
*[[Principles of protection]]
  
 
*[[Procedural values]]
 
*[[Procedural values]]
Line 805: Line 989:
  
 
*[[Projected dose]]
 
*[[Projected dose]]
 +
 +
*[[Protection quantities]]
  
 
*[[Protection strategy]]
 
*[[Protection strategy]]
Line 819: Line 1,005:
  
 
*[[Qualified expert]]
 
*[[Qualified expert]]
 +
 +
*[[Quality control testing]] (x-ray equipment)
  
 
*[[Quality factor]], Q(L)
 
*[[Quality factor]], Q(L)
Line 839: Line 1,027:
  
 
*[[Radiation weighting factor]], w<sub>R</sub>
 
*[[Radiation weighting factor]], w<sub>R</sub>
 +
 +
*[[Radiation-induced second cancer]]
 +
 +
*[[Radiation-induced secondary malignancy]]
  
 
*[[Radiation worker]]
 
*[[Radiation worker]]
Line 847: Line 1,039:
  
 
*[[Radioactive substance]]
 
*[[Radioactive substance]]
 +
 +
*[[Radioactive waste]]
  
 
*[[Radioactivity]]
 
*[[Radioactivity]]
Line 853: Line 1,047:
  
 
*[[Radiographer]]
 
*[[Radiographer]]
 +
 +
*[[Radiological attack]]
  
 
*[[Radiological controlled area]]
 
*[[Radiological controlled area]]
Line 865: Line 1,061:
  
 
*[[Radiosensitivity, cellular]]
 
*[[Radiosensitivity, cellular]]
 +
 +
*[[Radon progeny]]
 +
 +
*[[Radon-prone area]]
  
 
*RAP (see [[Reference Animal and Plant]])
 
*RAP (see [[Reference Animal and Plant]])
 +
 +
*[[Ras]]
 +
 +
*[[Rb]]
  
 
*RBE (see [[Relative biological effectiveness]])
 
*RBE (see [[Relative biological effectiveness]])
Line 879: Line 1,083:
  
 
*[[Recovery (cellular or tissue)]]
 
*[[Recovery (cellular or tissue)]]
 +
 +
*[[Redox]]
 +
 +
*[[Reference air kerma]]
  
 
*[[Reference Animal and Plant]]
 
*[[Reference Animal and Plant]]
Line 886: Line 1,094:
 
*[[Reference biokinetic model]]
 
*[[Reference biokinetic model]]
  
*Reference female (see [[Reference Individual]])
+
*[[Referrer]]
 +
 
 +
*Reference female (see [[Reference Person]])
  
 
*[[Reference individual]]
 
*[[Reference individual]]
Line 892: Line 1,102:
 
*[[Reference level]]
 
*[[Reference level]]
  
*Reference male (see [[Reference Individual]])
+
*Reference male (see [[Reference Person]])
  
 
*[[Reference parameter value]]
 
*[[Reference parameter value]]
Line 899: Line 1,109:
  
 
*[[Reference phantom]]
 
*[[Reference phantom]]
 +
 +
*[[Reference value]]
  
 
*[[Reference worker]]
 
*[[Reference worker]]
 +
 +
*[[Region]]
 +
 +
*[[Regional diagnostic reference levels]]
 +
 +
*[[Registry]]
  
 
*REID (see [[Lifetime risk estimates]])
 
*REID (see [[Lifetime risk estimates]])
 +
 +
*[[Rigidity threshold]]
  
 
*[[Rehabilitation of living conditions]]
 
*[[Rehabilitation of living conditions]]
Line 911: Line 1,131:
  
 
*[[Relative risk]]
 
*[[Relative risk]]
 +
 +
*[[Relative survival]]
  
 
*[[Relocation]]
 
*[[Relocation]]
Line 949: Line 1,171:
  
 
*[[Risk model]]
 
*[[Risk model]]
 +
 +
*RISM (see [[Radiation-induced secondary malignancy]])
  
 
*Risk of exposure-induced death (see (see [[Lifetime risk estimates]])
 
*Risk of exposure-induced death (see (see [[Lifetime risk estimates]])
Line 960: Line 1,184:
 
=== <big><span id="S">S</span></big> ===
 
=== <big><span id="S">S</span></big> ===
  
*[[S coefficient (radiation weighted)]] S<sub>W</sub>[(r<sub>T</sub>←r<sub>s</sub>)]
+
*[[S coefficient (radiation weighted)]]
  
* SAF (see [[Specific absorbed fraction]])
+
*SAF (see [[Specific absorbed fraction]])
  
 
*[[Safety case]]
 
*[[Safety case]]
 +
 +
*[[Safety]]
  
 
*[[Safety culture]]
 
*[[Safety culture]]
  
 
*[[Scintigraphy]]
 
*[[Scintigraphy]]
 +
 +
*[[Sealed source]]
 +
 +
*[[Secondary radiation]]
 +
 +
*[[Secretory cells]]
 +
 +
*[[Security]]
 +
 +
*[[Security screening]]
  
 
*SEE (see [[Specific effective energy]]]
 
*SEE (see [[Specific effective energy]]]
Line 977: Line 1,213:
  
 
*[[Severe deterministic injury]]
 
*[[Severe deterministic injury]]
 +
 +
*[[Sheltering]]
 +
 +
*[[Shielding]]
  
 
*[[Sievert]] (Sv)
 
*[[Sievert]] (Sv)
 +
 +
*[[Size-specific dose estimate]]
  
 
*SLDR (see [[Sublethal damage repair]])
 
*SLDR (see [[Sublethal damage repair]])
 +
 +
*[[Slice]] (in CT & CBCT)
  
 
*[[Slow repair]]
 
*[[Slow repair]]
 +
 +
*SOBP (see [[Spread-out Bragg peak]])
  
 
*[[Solar cosmic radiation]]
 
*[[Solar cosmic radiation]]
  
 
*[[Solar cycle]]
 
*[[Solar cycle]]
 +
 +
*[[Solar flare]]
  
 
*[[Solar particle event]]
 
*[[Solar particle event]]
Line 1,001: Line 1,249:
  
 
*[[Source-related]]
 
*[[Source-related]]
 +
 +
*[[Source-related assessment]]
  
 
*[[South Atlantic anomaly]]  
 
*[[South Atlantic anomaly]]  
Line 1,013: Line 1,263:
  
 
*[[Spontaneous fission]]
 
*[[Spontaneous fission]]
 +
 +
*[[Spread-out Bragg peak]]
  
 
*[[Stakeholder]]
 
*[[Stakeholder]]
 +
 +
*[[Standard-size adult]]
 +
 +
*[[Stem cell]]
  
 
*[[Stenosis]]
 
*[[Stenosis]]
Line 1,027: Line 1,283:
  
 
*[[Substantial radiation dose level]]
 
*[[Substantial radiation dose level]]
 +
 +
*[[Superposition principle]] (in dosimetry)
  
 
*[[Supervised area]]
 
*[[Supervised area]]
 +
 +
*[[Surface contamination]]
  
 
*[[Systemic model]]
 
*[[Systemic model]]
  
 
=== <big><span id="T">T</span></big> ===
 
=== <big><span id="T">T</span></big> ===
 
  
 
*[[Tachycardia]]
 
*[[Tachycardia]]
Line 1,044: Line 1,303:
  
 
*[[Telangiectasia]]
 
*[[Telangiectasia]]
 +
 +
*[[Teratocarcinoma]]
  
 
*[[Thermodynamic diameter]]
 
*[[Thermodynamic diameter]]
Line 1,051: Line 1,312:
 
*[[Threshold dose for tissue reactions]]
 
*[[Threshold dose for tissue reactions]]
  
*[[Threshold levels]]
+
*[[Threshold level]]
 +
 
 +
*Tissue absorbed dose (see [[Organ/tissue absorbed dose]])
  
*[[Tissue absorbed dose]] (see [[Organ/tissue absorbed dose]])
+
*[[Thoron progeny]]
  
 
*[[Thyroid blocking]]
 
*[[Thyroid blocking]]
  
 
*[[Time factor]]
 
*[[Time factor]]
 +
 +
*[[Time-resolved computed tomography]]
  
 
*[[Tissue equivalent material]]
 
*[[Tissue equivalent material]]
Line 1,066: Line 1,331:
  
 
*[[Tolerability]]
 
*[[Tolerability]]
 +
 +
*[[Tolerance dose]] (in Radiotherapy)
  
 
*[[Track structure]]
 
*[[Track structure]]
Line 1,080: Line 1,347:
  
 
*[[Translocation]]
 
*[[Translocation]]
 +
 +
*[[Transmission detection system]]
  
 
*[[Transparency]]
 
*[[Transparency]]
Line 1,088: Line 1,357:
  
 
*[[Trapped particles]]
 
*[[Trapped particles]]
 +
 +
*[[Treatment preparation in radiotherapy]]
 +
 +
*[[Trophic level]]
  
 
*[[Types of materials]]
 
*[[Types of materials]]
 +
 +
*[[Typical value]] (for DRL)
  
 
=== <big><span id="U">U</span></big> ===
 
=== <big><span id="U">U</span></big> ===
Line 1,096: Line 1,371:
  
 
*[[Unsealed source]]
 
*[[Unsealed source]]
 +
 +
*[[Upper reference levels]]
  
 
*[[Uptake]]
 
*[[Uptake]]
Line 1,114: Line 1,391:
  
 
*[[Waste disposal]]
 
*[[Waste disposal]]
 +
 +
*[[Waste management]]
  
 
*[[Wisdom]]
 
*[[Wisdom]]
 +
 +
*WL (see [[Working level]])
 +
 +
*WLM (see [[Working level month]])
 +
 +
*[[Worker]]
 +
 +
*[[Working level]]
 +
 +
*[[Working level month]]
  
 
*w<sub>T</sub> (see [[Tissue weighting factor]])
 
*w<sub>T</sub> (see [[Tissue weighting factor]])

Latest revision as of 14:37, 3 October 2021

Glossary Header-left2.png

The ICRP Glossary collects ICRP’s definitive explanations of terms for current use. Some entries include historical descriptions to help readers better understand the term in a particular context.

It is a living document, updated regularly.

Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.

Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ...

0-9

A

B

C

D

  • Dose (of ionising radiation)

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

...